Zymeworks Inc. SEC Filings

Zymeworks Inc. reported second-quarter 2026 results and a broad corporate update as it evolves into a diversified, revenue-generating biotechnology business. Total revenue was $4.6 million, compared with $48.7 million a year earlier, mainly because 2025 included significant non-recurring collaboration milestones and higher development support and drug supply revenue from Jazz. Research and development expenses declined to $27.4 million, while general and administrative expenses increased to $19.3 million, largely from higher stock-based compensation. Interest on a royalty-backed note financing with Royalty Pharma contributed to net other expense of $3.1 million, and the company posted a net loss of $45.0 million versus net income of $2.3 million in the prior-year quarter.

Cash, cash equivalents and marketable securities totaled $322.5 million as of June 30, 2026. Under its 2026 share repurchase program of up to $125.0 million, Zymeworks had used $49.4 million to buy 1,971,454 shares at an average price of $25.04, and since August 2024 has cumulatively repurchased $213.6 million of stock, leaving about 71.0 million shares outstanding. Strategically, an August 25, 2026 U.S. PDUFA target action date for zanidatamab could trigger a $250 million approval milestone, the first of up to $440 million in potential global regulatory milestones. The proposed acquisition of Theravance Biopharma, expected to close in the second half of 2026 and financed primarily by a $350 million non-recourse note and Theravance’s anticipated $360 million net cash, is expected to be accretive to earnings and generate positive cash flow, adding YUPELRI royalties, additional royalty and milestone interests, an early-stage I&I portfolio and $2.5 billion in Irish tax attributes. Zymeworks plans to stop providing cash runway guidance and instead focus its outlook on operating performance and long-term growth metrics.

Zymeworks Inc. executive Mark Hollywood, EVP & Chief Operating Officer, acquired 939 shares of common stock through the company’s Employee Stock Purchase Plan. The shares were bought for $22.22 each, reflecting a 15% discount to the closing price on June 30, 2026. After this ESPP purchase, he holds 133,852 common shares directly, so the new shares represent a small addition to his existing position.

Zymeworks Inc. is acquiring Theravance Biopharma in a cash deal designed to add durable commercial cash flows and expand its royalty-driven model. Under a definitive merger agreement, Zymeworks will buy all Theravance shares for $17.00 per share in cash, valuing the transaction at approximately $929 million, plus a non‑tradeable contingent value right (CVR) for each share tied mainly to future monetization of ampreloxetine and related milestones.

The deal adds YUPELRI, the only once‑daily nebulized LAMA approved in the U.S. for COPD maintenance, to Zymeworks’ partnered portfolio. Zymeworks expects YUPELRI to provide an anticipated long‑duration and potentially growing cash‑flow stream alongside existing Ziihera cash flows. The company plans to complete Theravance’s previously announced restructuring to reduce R&D and G&A spending while largely preserving its hospital sales infrastructure.

Financing combines $350 million of new senior secured non‑recourse notes from OMERS Life Sciences, backed by Theravance’s 35% YUPELRI profit share (with 75% of that share used to service the debt), roughly $219 million of Zymeworks cash, and about $360 million of Theravance cash at closing. Both parties agreed to reciprocal $32.515 million termination fees in defined circumstances. Closing is targeted for the second half of 2026, subject to HSR clearance and approval by at least two‑thirds of Theravance shares present and voting.

Schneider Paul R reported acquisition or exercise transactions in this Form 4 filing.

Zymeworks Inc. reported that EVP and General Counsel Paul R. Schneider received new equity compensation. On May 13, 2026, he was granted 119,000 restricted stock units, each representing one share of common stock upon vesting, and 178,000 stock options with a strike price of $24.57 per share.

The options vest 25% on the first anniversary of the grant and the remaining 75% in 36 equal monthly installments. The RSUs vest in four equal annual installments beginning on the first anniversary of the grant date. Following these awards, he holds 119,000 RSUs and 178,000 options directly.

Zymeworks Inc. executive vice president and general counsel Paul R. Schneider filed an initial Form 3 indicating he currently has no securities beneficially owned in the company. The filing lists holding entries showing zero shares and no derivative securities, so it reflects a baseline ownership position of none.

Zymeworks Inc. Schedule 13G/A filing: Rubric Capital Management and David Rosen report beneficial ownership of 7,000,000 shares of Zymeworks common stock, representing 9.49% of the class based on 73,749,607 shares outstanding as of February 6, 2026. The shares are held by Rubric Funds, including Rubric Capital Master Fund LP, which has voting and dispositive power shared among the Reporting Persons.

Zymeworks Inc. has authorized a new 2026 share repurchase program allowing it to buy back up to $125.0 million of its common stock. The Board terminated the prior 2025 program, under which Zymeworks repurchased 4,197,553 shares at an average price of $24.36, totaling $102.3 million. As of May 13, 2026, the company had about 73.0 million common shares outstanding. Zymeworks states that, based on current plans and assuming full execution of the new program, existing cash as of March 31, 2026 plus anticipated regulatory milestone payments of $440.0 million related to potential Ziihera approvals are expected to fund operations beyond 2028.

Zymeworks Inc. reported a first-quarter 2026 net loss of $44.2 million, wider than the prior year, as collaboration revenue fell to $2.4 million from milestone-heavy Q1 2025. Operating expenses were stable at $49.5 million, with research and development of $34.5 million and general and administrative of $15.1 million.

Cash, cash equivalents and marketable securities rose to $403.8 million as of March 31, 2026, helped by a $250.0 million non‑recourse term loan obtained through monetizing 30% of future Ziihera royalties, recorded as a $246.5 million liability. The company continued its share repurchase strategy, buying back 3.2 million shares for $76.6 million in the quarter. Zymeworks highlights upcoming regulatory milestones for Ziihera in HER2‑positive gastroesophageal cancers and ongoing development of its ADC and multispecific antibody pipeline.

Zymeworks Inc. reported first quarter 2026 results, with revenue of $2.4 million, down from $27.1 million a year earlier as prior non-recurring clinical milestone payments rolled off and collaboration and royalty revenue became the main drivers.

R&D expense was $34.5 million and G&A was $15.1 million, both slightly lower year over year, leading to a net loss of $44.2 million versus $22.6 million in 2025. Adjusted gross operating expense (non-GAAP) declined to $42.6 million from $46.3 million.

The company ended March 31, 2026 with $403.8 million in cash, cash equivalents and marketable securities and reiterated guidance for approximately $300 million in aggregate adjusted gross operating expenses over 2026–2028. It expects 2026 adjusted gross operating expenses to be about 20% lower than 2025 on a non-GAAP basis.

Zymeworks highlighted regulatory momentum for partnered HER2 antibody Ziihera (zanidatamab-hrii), including U.S. FDA Priority Review for first-line HER2-positive GEA with an August 25, 2026 PDUFA date and sBLA acceptances in China. Potential approval milestones across territories total $440 million.

The company continued to advance wholly owned ADC ZW191, reporting Phase 1 ovarian cancer data with confirmed objective response rates above 50% and high disease control rates, and presented a new RAS inhibitor ADC platform. It also used $95.8 million to repurchase 3.93 million shares under a $125 million buyback, leaving about 73.0 million shares outstanding.